Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities
Open Access
- 30 April 2019
- journal article
- review article
- Published by Elsevier BV in Trends in Cancer
- Vol. 5 (5), 297-307
- https://doi.org/10.1016/j.trecan.2019.04.001
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinomaOncology Reports, 2012
- Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAPGenes & Development, 2012
- MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survivalBlood, 2012
- The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer CellsCell, 2011
- Taxol Resistance in Breast Cancer Cells Is Mediated by the Hippo Pathway Component TAZ and Its Downstream Transcriptional TargetsCyr61andCTGFCancer Research, 2011
- The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase*Published by Elsevier BV ,2010
- MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor propertiesBiochemical and Biophysical Research Communications, 2010
- A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFβ-TRCPGenes & Development, 2010
- Identification of LATS transcriptional targets in HeLa cells using whole human genome oligonucleotide microarrayGene, 2010
- Down-regulation of Mammalian Sterile 20–Like Kinase 1 by Heat Shock Protein 70 Mediates Cisplatin Resistance in Prostate Cancer CellsCancer Research, 2008